Skip to main content

GREGORY A. SMALLWOOD, PHARMD, FCCP
Department of Pharmacy Practice
Clinical Coordinator of Experiential Education
Associate Professor


Gregory A. Smallwood, PharmD, FCCP

Contact

Email: gregorysm@pcom.edu
Office: 678-407-7342
Publications and Selected Works

Dr. Smallwood has more than 30 years experience as a practicing hospital pharmacist with 15 years as a clinical pharmacy specialist with a liver transplant team. He comes to PCOM School of Pharmacy from the School of Medicine at Emory University. He has published over 40 peer-reviewed articles, has made numerous national and international scientific presentations, is on the editorial board of Annals of Pharmacotherapy, and is a grant reviewer for the country of Qatar.

Dr. Smallwood has been an investigator or co-investigator of more than 40 human clinical trials. His research interest includes immunology, transplant, and diabetes with his most recent work being with the Immune Tolerance Network (ITN) using immunosuppressants in treating Type 1 diabetes which is funded by the National Institute of Allergy and Infectious Disease (NIAID) of the National Institute of Health (NIH).

  • Education

    PharmD, University of Georgia College of Pharmacy, 2001
    BS (Phr), University of Georgia College of Pharmacy,1979

  • Courses

    Dr. Smallwood currently coordinates several courses within the School of Pharmacy. He teaches the Clinical Pharmacy course for P3 students as well as coordinates the Sterile Laboratory associated with this course. He also teaches in several of the integrated therapeutics courses for the P3 students. For the P2 students in the School of Pharmacy he coordinates Pharmacokinetics.

  • Awards

    Honors/Awards

    Elected as a Fellow of the American College of Clinical Pharmacy (ACCP). October 21, 2012 at the 2012 Annual Meeting in Hollywood, Florida.

    President Choice Award, Emergence of drug resistance cytomegalovirus following liver transplantation. American Association for the Study of Liver Disease (AASLD) annual meeting. November 12-15, 2005; San Francisco, CA

    Recipient of an Award of Excellence in Pharmacy. Relationship between immunosuppression and osteoporosis in an outpatient liver transplant clinic. 3rd International Congress on Immunosuppression. December, 2004 - Manchester Grand Hyatt San Diego, San Diego, CA

    President Choice Award, Increased survival in pediatric acute hepatic failure following liver transplantation with early surgical intervention utilizing living donor, partial grafts, and ABO incompatible grafts. American Association for the Study of Liver Disease (AASLD) annual meeting. November 2005; San Francisco, CA

  • Memberships

    Volunteer and Leadership:

    Community Advisory Panel (CAP) Member for the PBRN (Practice Based Research Network) of the American College of Clinical Pharmacist (ACCP)

    Member of the Institutional Review Board (IRB), Biomedical Committee Emory University, Atlanta, Ga

    Frontiers – PRN Representative, American College of Clinical Pharmacist (ACCP)

    Planning committee for the Immune Tolerance Network (ITN) sponsored by NIAID entitled: ITN045AI: Multicenter, randomized trial entitled: Inducing Remission in New Onset T1DM with Alefacept (Amevive®).

    International Committee member to develop a non-adherence consensus statement in solid organ transplantation for the American Society of Transplantation(AST), American Society of Transplant Surgeons(ASTS), and the International Pediatric Transplant Society(IPTS)

    Enhancing Wellness: Lifelong Success for the Transplant Patient website. Health Maintenance Committee, American Society of Transplantation (AST). November 2005

    Planning committee member for the Baylor HCV project following liver transplantation sponsored by Baylor Medical Center and Roche

  • Grants

    • A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day - Sponsored by Lifecycle Pharma
    • An Open Label Phase II Extension Study for Patients Completing Study LCP-Tacro 2012 (An Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day) – Sponsored by Lifecycle Pharma
    • “Comparison of mycophenolate mofetil (CellCept®) pharmacokinetics of mycophenolic acid (MPA) to enteric coated mycophenolate sodium (Myfortic®) in stable, long-term liver transplant recipients - Sponsored by F. Hoffmann-La Roche Ltd.
    • “A randomized, controlled, multicenter study of Thymoglobulin induction therapy with a calcineurin-inhibitor sparing regimen in liver transplant patients.” - Sponsored by SangStat Medical Corporation